Corporate Responsibility

August 15, 2023 Alnylam Named a Humankind 100 Company for the Second Year in a Row Alnylam has been named to the HumanKind 100 list for the 2nd year in a row and we’re pleased to have moved up in the rankings from #97 in 2022 to #76 in 2023. Read More ›
June 23, 2023 Alnylam in the Community: CASPAR Partnership Highlight Alnylam has partnered with community organization CASPAR (Cambridge And Somerville Programs for Addiction Recovery) for many years. Read More ›
May 3, 2023 Building a Corporate Responsibility Program from the Ground Up: Key Learnings from Alnylam ... If you are building your program or assessing your program, here are five key learnings which may be helpful to your organization Read More ›
December 8, 2022 Alnylam Named One of America's Most Responsible Companies by Newsweek Alnylam has been named one of America's Most Responsible Companies for 2023 by Newsweek and research firm Statista Read More ›
June 20, 2022 Challenging Ourselves to Help Refugees: Supporting Refugees to Become Work-Ready Alnylam has announced a three-year corporate partnership with Refugee Action, a United Kingdom (UK)-based charity dedicated to helping refugees... Read More ›
March 16, 2022 Alnylam Publishes 2021 Corporate Responsibility Report We're committed to taking bold actions that improve the health of humanity. Our 2021 Corporate Responsibility Report provides details on our progress... Read More ›
December 21, 2021 Alnylam Publishes 2021 Patient Access Philosophy Report Alnylam has published its 2021 Patient Access Philosophy Report detailing its actions as a company to provide access to its medicines for those who may... Read More ›
October 13, 2021 Alnylam Challengers - a Health Equity Community Impact Program Alnylam Challengers is Alnylam's signature CSR Community Impact Program. It aims to improve health access to underserved communities. Read More ›
March 11, 2021 Alnylam Publishes First Corporate Responsibility Summary Today, we've published Alnylam's first Corporate Responsibility Summary detailing our approach to corporate responsibility and the actions we are and intend... Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site